|drug3236||Standard of care management Wiki||1.00|
|drug3221||Standard of Care Wiki||0.16|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
This is a phase II, multicenter, open-label, randomized, comparator-controlled study to evaluate the efficacy and safety of Pegylated Interferon -α2b in the treatment of adult patients diagnosed with SARS-CoV2 (COVID-19).Initial 1 mcg/kg of Pegylated Interferon-α2b will be administered on day 1. After safety evaluation of first dose, next dose (second dose) 1 mcg/kg on day 8 will be administered with recommended standard care during the trial.
Description: Not hospitalized, no limitations on activities. Not hospitalized, limitation on activities. Hospitalized, not requiring supplemental oxygen. Hospitalized, requiring supplemental oxygen. Hospitalized, on non-invasive ventilation or high flow oxygen devices. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO). Death.Measure: Change in Clinical status of subject on a 7-point ordinal scale Time: Week 2
Description: PCR for SARS-CoV-2 in pharyngeal swabMeasure: PCR test Time: Week 2 and Week 4
Description: Occurrence of supplemental OxygenMeasure: Supplemental Oxygen Time: Week 2 and Week 4
Description: Occurrence of Mechanical VentilationMeasure: Mechanical Ventilation Time: Week 2 and Week 4
Description: Occurence of Adverse eventsMeasure: Incidence of Treatment-Emergent Adverse Events Time: Week 2 and Week 4
Description: Inflammatory BiomarkerMeasure: C-reactive protein (CRP) Time: Week 2 and Week 4
Description: Inflammatory BiomarkerMeasure: Interleukin 6 (IL-6) Time: Week 2 and Week 4
Description: Inflammatory BiomarkerMeasure: D-dimer Time: Week 2 and Week 4
Description: type II class of interferonsMeasure: Interferon gamma Time: Week 2 and Week 4
Description: proteinsMeasure: Ferritin Time: Week 2 and Week 4
Description: Inflammatory BiomarkerMeasure: TNF alpha Time: Week 2 and Week 4
Description: Inflammatory BiomarkerMeasure: Interleukin 1-β Time: Week 2 and Week 4
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports